Actively Recruiting
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
Led by Beijing Tiantan Hospital · Updated on 2024-12-27
792
Participants Needed
18
Research Sites
282 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone for symptomatic intracranial atherosclerotic disease.
CONDITIONS
Official Title
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age from 18 to 85 years
- Ischemic stroke within 30 days before enrollment attributed to 70% to 99% stenosis of a major intracranial artery (internal carotid artery [C4-C7], middle cerebral artery [M1], vertebral artery [V4], or basilar artery) confirmed by CTA
- Diameter of the target vessel between 2.0 mm and 4.5 mm
- Length of the stenosis lesion 64 14 mm
- Baseline modified Rankin Scale (mRS) score 64 3
- Patient understands the study purpose and has provided informed consent
You will not qualify if you...
- Ischemic stroke occurred within 7 days before enrollment
- Tandem extracranial or intracranial stenosis (70%-99%) or occlusion proximal or distal to the target lesion, except for specific vertebral artery cases
- Bilateral intracranial vertebral artery stenosis (70%-99%) with uncertainty about symptomatic side, except if dominant side can be identified
- Unilateral vertebral artery stenosis (70%-99%) with normal contralateral vertebral artery
- Stroke caused by perforating artery occlusion
- Severe calcification at target lesion on CT angiography
- History of brain parenchymal or subarachnoid, subdural or extradural hemorrhage in past 6 weeks
- Intracranial artery stenosis caused by non-atherosclerotic lesions such as arterial dissection, Moyamoya disease, vasculitis, viral vascular diseases, neurosyphilis, intracranial infections, radiation-induced vascular disease, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, CNS benign vascular disease, postpartum vascular disease, suspected vasospasm, or embolism recanalization
- History of stenting of an intracranial artery
- Presence of any definite cardiac source of embolism
- Combined intracranial tumor, aneurysm, or arteriovenous malformation
- Inability to tolerate dual antiplatelet therapy
- Contraindications to heparin, rapamycin, contrast agents, or anesthesia
- Hemoglobin less than 100 g/L or platelet count less than 100�d7109/L
- Severe liver or kidney dysfunction
- INR greater than 1.5 or uncorrectable bleeding risk factors
- Major surgery within past 30 days or planned within 90 days
- Need for simultaneous intervention of renal, iliac, or coronary arteries
- Life expectancy less than 1 year
- Pregnant or breastfeeding women
- Inability to complete follow-up due to cognitive, emotional, or mental illness
- Other conditions judged unsuitable by the investigator
- Enrollment in conflicting studies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China, 100070
Actively Recruiting
2
Beijing Daxing District People's Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
3
Hejian People's Hospital
Cangzhou, Hebei, China
Actively Recruiting
4
North China University of Science and Technology Affiliated Hospital
Tangshan, Hebei, China
Actively Recruiting
5
Xingtai City Third Hospital
Xingtai, Hebei, China
Actively Recruiting
6
General Hospital of The Yangtze River Shipping
Wuhan, Hubei, China
Actively Recruiting
7
Baotou Central Hospital
Baotou, Inner Mongolia, China
Actively Recruiting
8
Inner Mongolia Autonomous Region People's Hospital
Hohhot, Inner Mongolia, China
Actively Recruiting
9
Tongliao City Hospital
Tongliao, Inner Mongolia, China
Actively Recruiting
10
Wuhai People's Hospital
Wuhai, Inner Mongolia, China
Actively Recruiting
11
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Actively Recruiting
12
The Second Norman Bethune Hospital of JilinUniversity,
Changchun, Jilin, China
Actively Recruiting
13
General Hospital of Benxi Iron and Steel Co
Benxi, Liaoning, China
Actively Recruiting
14
Shanxi Cardiovascular Hospital
Taiyuan, Shanxi, China
Actively Recruiting
15
Shanxi Provincial People's Hospital
Taiyuan, Shanxi, China
Actively Recruiting
16
The First Affiliated Hospital of College of Medicine
Hangzhou, Zhejiang, China
Actively Recruiting
17
Lishui People's Hospital
Lishui, Zhejiang, China
Actively Recruiting
18
Beilun People's Hospital of Ningbo City
Ningbo, Zhejiang, China
Actively Recruiting
Research Team
N
Ning Ma, MD
CONTACT
B
Baixue Jia, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here